These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 26005000)

  • 1. The multiple myeloma bone eco-system and its relation to oncogenesis.
    Bataille R
    Morphologie; 2015 Jun; 99(325):31-7. PubMed ID: 26005000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanisms for formation of myeloma bone disease].
    Yata K; Abe M; Matsumoto T
    Clin Calcium; 2008 Apr; 18(4):438-46. PubMed ID: 18379024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma.
    Bataille R; Chappard D; Klein B
    Int J Clin Lab Res; 1992; 21(4):283-7. PubMed ID: 1591381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the pathogenesis of osteolysis in multiple myeloma patients.
    Giuliani N; Colla S; Rizzoli V
    Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathogenesis of myeloma bone disease.
    Roodman GD
    J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of bortezomib on bone disease in patients with multiple myeloma.
    Mohty M; Malard F; Mohty B; Savani B; Moreau P; Terpos E
    Cancer; 2014 Mar; 120(5):618-23. PubMed ID: 24249482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of myeloma bone disease.
    Roodman GD
    Leukemia; 2009 Mar; 23(3):435-41. PubMed ID: 19039321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathophysiology of multiple myeloma bone disease.
    Lentzsch S; Ehrlich LA; Roodman GD
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1035-49, viii. PubMed ID: 17996587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytokines in bone diseases. Cytokines and myeloma bone disease].
    Abe M
    Clin Calcium; 2010 Oct; 20(10):1474-80. PubMed ID: 20890028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-host cell interactions in the bone disease of myeloma.
    Fowler JA; Edwards CM; Croucher PI
    Bone; 2011 Jan; 48(1):121-8. PubMed ID: 20615487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for the secretion of an osteoclast stimulating factor in myeloma.
    Mundy GR; Raisz LG; Cooper RA; Schechter GP; Salmon SE
    N Engl J Med; 1974 Nov; 291(20):1041-6. PubMed ID: 4413338
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanisms of bone lesions in multiple myeloma.
    Bataille R; Chappard D; Klein B
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):285-95. PubMed ID: 1582975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.
    Hurchla MA; Garcia-Gomez A; Hornick MC; Ocio EM; Li A; Blanco JF; Collins L; Kirk CJ; Piwnica-Worms D; Vij R; Tomasson MH; Pandiella A; San Miguel JF; Garayoa M; Weilbaecher KN
    Leukemia; 2013 Feb; 27(2):430-40. PubMed ID: 22763387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of myeloma bone disease.
    Roodman GD
    Blood Cells Mol Dis; 2004; 32(2):290-2. PubMed ID: 15003820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloma cell-induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast-myeloma hybrid cells.
    Andersen TL; Søe K; Sondergaard TE; Plesner T; Delaisse JM
    Br J Haematol; 2010 Feb; 148(4):551-61. PubMed ID: 19919653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bone disease in multiple myeloma and its mechanism].
    Abe M
    Clin Calcium; 2006 Apr; 16(4):565- 71. PubMed ID: 16582506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.
    Bataille R; Chappard D; Marcelli C; Dessauw P; Baldet P; Sany J; Alexandre C
    J Clin Invest; 1991 Jul; 88(1):62-6. PubMed ID: 2056131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
    Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
    Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.
    Kassen D; Lath D; Lach A; Evans H; Chantry A; Rabin N; Croucher P; Yong KL
    Br J Haematol; 2016 Jan; 172(1):64-79. PubMed ID: 26767468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.